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Abstract
Background: This study aims at characterizing the in vitro metabolism of cryptolepine using human and rat
hepatocytes, identifying metabolites in rat plasma and urine after a single cryptolepine dose, and evaluating the
single-dose oral and intravenous pharmacokinetics of cryptolepine in male Sprague Dawley (SD) rats.
Methods: The in vitro metabolic profiles of cryptolepine were determined by LC-MS/MS following incubation with
rat and human hepatocytes. The in vivo metabolic profile of cryptolepine was determined in plasma and urine
samples from Sprague Dawley rats following single-dose oral administration of cryptolepine. Pharmacokinetic
parameters of cryptolepine were determined in plasma and urine from Sprague Dawley rats after single-dose
intravenous and oral administration.
Results: Nine metabolites were identified in human and rat hepatocytes, resulting from metabolic pathways
involving oxidation (M2-M9) and glucuronidation (M1, M2, M4, M8, M9). All human metabolites were found in rat
hepatocyte incubations except glucuronide M1. Several metabolites (M2, M6, M9) were also identified in the urine
and plasma of rats following oral administration of cryptolepine. Unchanged cryptolepine detected in urine was
negligible. The Pharmacokinetic profile of cryptolepine showed a very high plasma clearance and volume of
distribution (Vss) resulting in a moderate average plasma half-life of 4.5 h. Oral absorption was fast and plasma
exposure and oral bioavailability were low.
Conclusions: Cryptolepine metabolism is similar in rat and human in vitro with the exception of direct glucuronidation
in human. Clearance in rat and human is likely to include a significant metabolic contribution, with proposed primary
human metabolism pathways hydroxylation, dihydrodiol formation and glucuronidation. Cryptolepine showed extensive
distribution with a moderate half-life.
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Background
Malaria is a major cause of morbidity and mortality, es-
pecially in Africa [1, 2]. The disease is commonly found
in the tropical and subtropical regions of the world with
about 214 million new cases and 438,000 deaths re-
ported in 2015 worldwide [3]. According to the WHO
[3], 90% of all malaria deaths reported in 2015 occurred
in sub-Saharan Africa. Despite the reduction in malaria
morbidity and mortality between 2000 and 2015, the
major problem associated with further reduction or
complete eradication of this disease is the increasing re-
sistance of Plasmodium falciparum to most of the com-
monly used antimalarial drugs.
Traditional medicines have been a major starting point
for the development of antimalarial agents [4]. Quinine
and artemisinin and their derivatives are important
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examples thereof [5]. Cryptolepis sanguinolenta (Lindl.)
Schlechter is a popular Central- and West-African
climbing shrub used over decades by African traditional
healers for the treatment of fevers including malaria,
hepatitis, bacterial infections and as antirheumatic and
spasmolytic agents [6–8]. In Ghana, a clinical trial using a
herbal tea bag preparation (containing Cryptolepis sangui-
nolenta) studied in forty four patients with clinical fea-
tures of uncomplicated malaria showed more than half of
the patients cleared of P. falciparum parasitaemia within
72 h (mean clearance = 82.3 h) [9]. The safety and efficacy
studies of this popular antimalarial plant has brought hope
to several millions of people who are affected by malaria
in Ghana and other West African countries. On the
Ghanaian market in 2015, there were fifteen (15) formu-
lated herbal products containing C. sanguinolenta for the
treatment of malaria (unpublished data). Cryptolepine
(Fig. 1) is the major indoloquinoline alkaloid isolated
from the plant and reported to possesses a number of
pharmacological activities including potent activity against
both chloroquine-sensitive (strain D6) and chloroquine-
resistant Plasmodium falciparum (strain K1, W2) in
vitro [10].
Despite extensive studies on the biological effects of
cryptolepine, very little is known about its mechanisms
of biotransformation in human and the widely used pre-
clinical species, rat. The only work on the biotransform-
ation of cryptolepine remains that of Stell et al. (2012)
[11], who found cryptolepine to be oxidized by rabbit
liver aldehyde oxidase forming cryptolepine-11-one which
is inactive against P. falciparum in vitro. This finding
could potentially limit the effectiveness of cryptolepine as
an antimalarial agent, as aldehyde oxidase metabolism is
often very rapid in human [12].
In previous pharmacokinetic reports by two independ-
ent researchers in rats and mice, cryptolepine showed a
rapid disappearance from the plasma and localization in
various tissues except the central nervous system and
concluded that the hepatobiliary tract could be the main
clearance pathway of cryptolepine [13, 14]. In contrast,
McCurrie and colleagues [15] detected cryptolepine hydro-
chloride in the serum up to 10 h after oral administration
of 10 mg/kg to rats and reported that no cryptolepine me-
tabolites were detected in the serum samples. Similarly,
Kuntworbe et al. (2013) [16] detected cryptolepine up to
24 h after 10 mg/kg intravenous administration to rats.
The lack of metabolic pathway information and the un-
clarity with regards to plasma metabolites and pharmaco-
kinetics of cryptolepine led to the present study. This
study aims at evaluating the metabolic profile and the
mechanisms of biotransformation of cryptolepine by (1)
characterization of metabolites following in vitro metabol-
ism of cryptolepine in human and rat hepatocytes, (2)
identification of the metabolites present in rat plasma and
urine after single dose administration as well as (3) evalu-
ation of the single-dose pharmacokinetics (PK) of crypto-
lepine in male Sprague Dawley (SD) rats.
Materials and methods
Reagents
Cryopreserved hepatocytes from human and rat were
obtained from Celsis In Vitro Technologies (Baltimore,
MD). Pooled plasma (K2 EDTA) from male Sprague
Dawley rat was purchased from BioreclamationIVT
(Westbury, NY). Cryptolepine hydrate and glyburide
were purchased from Sigma Aldrich (St. Louis, MO).
Acetonitrile, formic acid, and dimethyl sulfoxide were
purchased from Thermo Fisher Scientific Inc. (Rockford,
IL).
In vitro metabolite profiling in hepatocytes
Mixed gender pooled cryopreserved, suspension hepato-
cytes were obtained from Bioreclamation IVT (catalogue
numbers M00005 for rat and X008001 for human) and
stored in the gas phase over liquid nitrogen until use. All
experiments were carried out using Williams medium E
supplemented with fetal bovine serum (10%). Stock solu-
tions of test compounds (2 mM) were prepared in DMSO.
Thawed hepatocytes (37 °C, 2 min) was transferred to a
tube containing incubation medium (40 mL, 37 °C). The
suspension was centrifuged for 1 min at 50 g at room
temperature, and then the supernatant was removed and
discarded. The hepatocyte pellet was resuspended in
William medium E by gentle agitation in a small vol-
ume (2–5 mL) of incubation medium. An aliquot of cell
suspension (50 μL) was mixed with trypan blue (50 μL)
for viability assessment and cell counting. An appropri-
ate volume of incubation medium was then added to
the remaining cell suspension to give a final concentra-
tion 1 × 106 viable cells/mL. Cell suspension (1 mL) was
transferred to wells of a 12 well plate, and cryptolepine
(10 μM) was added. The concentration of DMSO in the
final wells were less than 0.1%. The samples were then
incubated at 37 °C under an atmosphere of 75% O2, 5%
Fig. 1 Structure of cryptolepine
Forkuo et al. BMC Pharmacology and Toxicology  (2017) 18:84 Page 2 of 9
CO2, 20% N2; 98% humidity with shaking (50 rpm) in a
HERAcell 240i incubator (Thermo Fischer Scientific,
Waltham, MA, USA). Incubations were initiated by the
addition of cryptolepine to the hepatocytes. At each
time point (0, 4, 24 h), 200 μL of incubation sample
was added to 1 volume of chilled acetonitrile (0 °C), in-
ternal standard was added (8 μL, final concentration
5 μM), and the mixture was frozen at −80 °C.
Analytical methods for metabolite profiling in
hepatocytes
Samples were centrifuged at 10000 g at 4 °C for 5 min and
supernatants (100 μL) were diluted with water (400 μL)
and filtered (0.45 μm). Samples were analyzed by Capillary
HPLC-MS/MS using a Chorus 200 binary syringe pump
(CS Analytics, Beckenried, Switzerland), Triart C18 col-
umn (1.9 μm particle size, 150 mm × 0.3 mm) at 40 °C
coupled to an LTQ Orbitrap XL mass spectrometer
(Thermo Fisher Scientific, Waltham, MA, USA). Electro-
spray ionization in positive mode was used, recording full
scans (m/z 150–1500) at resolution 30,000, and targeted
or data dependent MSn at unit resolution or high (30000)
resolution as required for metabolite characterization.
Chromatographic separation was achieved with the fol-
lowing mobile phases, (A): 10 mM ammonium formate in
MS-grade water, MS-grade water/ acetonitrile (95:5), and
0.02% Trifluoroacetic acid; (B): MS-grade water/ methanol
(5:95), 10 mM ammonium formate in MS-grade water,
0.02% Trifluoroacetic acid. A linear gradient of mobile
phase B from 2 to 95% was applied over 25 min on the
column at a flow rate of 4.5 μL/min. Experiments for the
determination of exchangeable protons were performed
by exchange of H2O by D2O (deuterated water) and
CH3OH by CH3OD (deuterated methanol).
Studies of cryptolepine in rats
Male Sprague Dawley rats, 320–340 g, purchased from
Envigo Rms, Inc., Dublin, VA were used in the study.
The experimental protocol was approved by the Novartis
Institutes for Biomedical Research Cambridge Institutional
Animal Care and Use Committee (approval August 2014).
All rats were housed under constant environmental condi-
tions (21 ± 2 °C, 40 ± 5% humidity, and 12-h light-dark cy-
cles) and were allowed free access to food and water. The
rats were fasted overnight (20 h) before oral dosing but
food was returned to animals 4 h post p.o. dose.
Cryptolepine was administered intravenously and orally
at doses of 1 and 5 mg/kg, respectively (n = 2 for each
route of administration). Cryptolepine was dissolved in
1 N NaOH/PEG300/Cremophor EL/Solutol/phosphate
buffered saline (1:30:5:5:59% volume) for intravenous ad-
ministration (via a catheter in the left jugular vein). For
oral administration, cryptolepine was suspended in Tween
80/methylcellulose/water (0.5:0.5:99.5% volume/weight/
volume). Blood samples were collected from the animals
at 5, 15, 30 min and 1, 2, 4, 7 and 24 h post intravenous
dose and at 15 and 30 min and 1, 2, 4, 7 and 24 h post oral
dose via a catheter in the right jugular vein. Rats were
euthanized by cardiac puncture at the last blood collection
time point. Urine was also collected at 0–7 and 7–24 h
time intervals after both routes of administration. Plasma
was obtained from blood samples by centrifugation at
8161 g for 2 min.
In vivo metabolite profiling in SD rat urine and plasma
The plasma samples were pooled according to the Hamilton
pooling method [17]. Pooled samples were extracted with 2
volumes of chilled acetonitrile with 0.1% formic acid. There-
after, the supernatants volume was reduced to ca. 30 μL
under a gentle stream of nitrogen gas. 2 mL of pooled urine
samples (approximately 20% volume of each time point for
each animal) were centrifuged at 4000 rpm for 3 min to re-
move any particles.
Analytical methods for metabolite profiling in SD rat urine
and plasma
Sample analysis and metabolite identification were car-
ried out on a Thermo LTQ-Orbitrap mass spectrometer
(Thermo Fisher Scientific, Waltham, MA) interfaced
with a 3 Ti high-performance LC pump and CTC PAL
autosampler (LEAP Technologies, Carrboro, NC). The
analytes were separated on a Waters Symmetry C18 ana-
lytical column (5 μm particle size, 2.1 × 150 mm; Waters,
Milford, MA) with a 35-min gradient elution method.
The mobile phases consisted of (A) 10 mM ammonium
formate in MS-grade water and (B) MS-grade aceto-
nitrile. The sample aliquots were eluted at a flow rate of
0.25 mL/min with 10% B over 5 min. Mobile phase (B)
was gradually increased to 90% over 24 min. The col-
umn was then returned to 10% B and held for 3 min be-
fore the next injection.
Structural characterization of metabolites
The structural characterization of metabolites in plasma,
urine and in vitro samples was carried out by MS/MS
analysis after LC separation of analytes (described above).
High resolution MS and MS/MS spectra with collision-
induced dissociation were obtained in positive ion mode.
The structures of the metabolites were determined based
on their elemental composition by exact mass measure-
ment, MS/MS fragmentations, and number of exchange-
able hydrogens based on hydrogen-deuterium exchange in
deuterated solvent.
Quantification of Cryptolepine in rat plasma and urine
Urine samples were diluted in 1 volume of blank rat
plasma. All plasma and urine samples were then diluted 6-
fold in acetonitrile containing internal standard (glyburide)
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and centrifuged (5000 g at 4 °C for 30 min) to precipitate
proteins. The supernatant samples were then analysed by
LC-MS/MS. The analytical system consisted of an API
4000 instrument mass spectrometer (AB Sciex, Foster City,
CA), coupled to an Agilent 1200 system (Agilent Technolo-
gies, Inc., Santa Clara, CA) and a CTC HTS PAL autosam-
pler (LEAP Technologies, Carrboro, NC). Analytes in
plasma and urine samples were separated using an ACE
C18 HPLC column (3 μm, 30 mm× 2.1 mm i.d. MAC-
MOD Analytical, Inc. Chadds Ford, PA). The column was
eluted using an isocratic gradient over 3.5 min with mobile
phase consisting of 0.1% formic acid in water (solvent A)
and 0.1% formic acid in acetonitrile (solvent B) at a flow
rate of 0.7 mL/min. Cryptolepine was detected by multiple
reaction monitoring (MRM) transition of 233→ 190 under
positive ion mode. The internal standard, glyburide, an
MRM transition of 494→ 169 was used. Linearity of cali-
bration curves of cryptolepine were confirmed between 0.1
and 5000 ng/ml.
Pharmacokinetic analysis
Non compartmental pharmacokinetic analysis was per-
formed using Phoenix 6.3 (Certara, St Louis, MO, USA)
to determine the following pharmacokinetic parameters;
area under the plasma concentration time curve (AUC),
maximum plasma concentration (Cmax), time to reach
Cmax (Tmax), plasma clearance (CLp), steady state volume
of distribution (Vss), elimination half-life of plasma con-
centration (t1/2), mean residence time of plasma concen-
tration (MRT) and oral bioavailability (% F). Amount
excreted in urine (Ae) was calculated from measured
urine concentrations and volumes.
Results
Hepatocyte incubation and metabolite identification
Metabolites were identified in hepatocyte incubates by
analysis of high resolution LC-MS/MS data. Nine metabo-
lites were identified in human and rat hepatocytes (see
Table 1 for MS data and Figs. 2 and 3 for proposed struc-
tures and a representative mass chromatogram) resulting
from metabolic pathways mainly involving hydroxylation
(M2, M4, M6, M7, M8, M9), proposed dihydrodiol forma-
tion (M3, M5) and glucuronidation (M1, M2, M4, M8,
M9). All metabolites were detected in hepatocyte incuba-
tions from both species except for glucuronide M1, which
was only formed by human hepatocytes, and metabolites
M8 and M9, which were only formed by rat hepatocytes.
Based on the proposed metabolism pathways (Fig. 4),
the apparent primary metabolites are hydroxylation
(M6/M7), dihydrodiol formation (M3), and glucuroni-
dation (M1).
Metabolites in rat urine and plasma
Plasma and urine following oral administration of 5 mg/
kg cryptolepine were also analyzed for metabolites by
Table 1 LC-MS data for cryptolepine and proposed metabolites
Metabolite
code
Retention
time (min)
Measured
m/z
Proposed MH+
formula
Product ions m/z and proposed
neutral loss formula
m/z after H/D
exchange
Detected in
hepatocyte
species
Detected in rat
plasma/urine
M1 12.9 409.1394 C22H21N2O6 233 (-C6H9O6); MS3 218 (-CH3) 413 H
M2 14.8 425.1344 C22H21N2O7 249 (-C6H9O6); MS3 221 (-CO),
234 (-CH3)
430 R, H Urine
M3 14.8 267.1129 C16H15N2O2 221 (-CH2O2), 239 (-CO), 249
(-H2O), 252 (-CH3)
270 R, H
M4 15.8 425.1343 C22H21N2O7 249 (-C6H9O6); MS3 221 (-CO),
234 (-CH3)
430 R, H
M5 17.1 283.1078 C16H15N2O3 211 (-C3H4O2), 225 (-C3H6O), 237
(-CH2O2), 239 (-C2H4O), 255 (-CO),
265 (-H2O), 268 (-CH3)
287 R, H
M6 18.1 249.1023 C16H13N2O 221 (-CO), 231 (-H2O), 234 (-CH3),
235 (-CH2)
251 R, H Urine, plasma
Cryptolepine 18.5 233.1073 C16H13N2 218 (-CH3), 219 (-CH2) 234 R, H Urine
M7 18.6 249.1022 C16H13N2O 221 (-CO), 231 (-H2O), 234 (-CH3),
235 (-CH2)
251 R, H
M8 18.7 441.1294 C22H21N2O8 222 (-C6H9O6 - C2H3O), 237(-C6H9O6 -
CO), 247(-C6H9O6 - H2O), 250(-C6H9O6 -
CH3), 265 (-C6H9O6)
447 R
M9 19.2 441.1292 C22H21N2O8 222 (-C6H9O6 - C2H3O), 237(-C6H9O6 -
CO), 247(-C6H9O6 - H2O), 250(-C6H9O6 -
CH3), 265 (-C6H9O6)
447 R Urine
R: rat; H: human
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Fig. 2 Proposed metabolite structures and metabolic pathways for cryptolepine determined by LC-MS/MS after incubation with rat and human
hepatocytes for up to 24 h and in plasma and urine of SD rats after single dose oral administration of cryptolepine. R: detected after rat hepatocyte
incubation; H: detected after human hepatocyte incubation. * Metabolite detected in rat urine; ** metabolite detected in rat urine and plasma
Fig. 3 Representative extracted ion chromatogram for cryptolepine and proposed metabolites formed in rat hepatocytes after 24 h of incubation.
M1 is not shown as it was only detected in the human hepatocyte incubation
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LC-MS/MS. All of the metabolites identified were also
detected in rat hepatocyte incubations. A total of three
metabolites were detected in SD rat urine (M2, M6, M9)
and one metabolite was detected in plasma (M6). Metab-
olism included; oxidation (M6), oxidation and glucur-
onidation (M2), and di-hydroxylation followed by
glucuronidation (M9). Metabolites M2 and M9 were
observed in urine only.
Pharmacokinetic profile of cryptolepine in rat
The pharmacokinetics of cryptolepine in rat were inves-
tigated following 1 mg/kg intravenous and 5 mg/kg oral
administration. The plasma concentration-time profiles
for cryptolepine are shown in Figs. 4 and 5, and pharma-
cokinetic parameters are shown in Tables 2 and 3. Fol-
lowing both intravenous and oral administration, plasma
concentrations were quantifiable up to and including the
Fig. 4 Plasma concentration-time profiles of cryptolepine after single intravenous (1 mg/kg) administrations to Sprague Dawley rats. The lower
dotted line indicates the LLOQ (2.2 nM) of LC–MS/MS method for quantifying cryptolepine in rat plasma
Fig. 5 Plasma concentration-time profiles of cryptolepine after single oral (5 mg/kg) administration to Sprague Dawley rats. The lower dotted line
indicates the LLOQ (2.2 nM) of the LC–MS/MS method for quantifying cryptolepine in rat plasma
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7 h sampling time point, and pharmacokinetics were cal-
culated based on a Tlast of 7 h. Plasma exposure was
low and the average plasma clearance (CLp) was high.
Cryptolepine was extensively distributed as indicated by
the high volume of distribution (Vss), resulting in a
moderate plasma t1/2. Absorption after oral administra-
tion was fast with Cmax values of 28 nM and 104 nM
reached within 0.25 and 0.5 h in animals 3 and 4 re-
spectively. Oral bioavailability was low (16% and 28% in
animals 3 and 4, respectively). Less than 1% of dose was
excreted unchanged in urine within 24 h post dosing.
Discussion
The results of our present investigation with cryptolepine
shed light on the metabolic profile and the mechanisms of
biotransformation of cryptolepine in vitro in human and
rat hepatocytes and in vivo in Sprague Dawley rats. Com-
mercially available metabolically active hepatocytes have
been shown to contain the complete complement of drug-
metabolizing enzymes and hence serves as the closest in
vitro surrogate for in vivo hepatic metabolism [18]. The
metabolic profiles in rat and human were compared to as-
sess potential metabolic clearance pathways, and whether
all metabolites observed in human matrices were detected
in the rodent species. Incubation of cryptolepine in rat
and human hepatocytes for 24 h showed nine major
metabolites. These identified metabolites lead to the
proposed metabolism pathway shown in Fig. 2, with
primary metabolism pathways in human and rat being
hydroxylation and dihydrodiol formation, as well as
glucuronidation in human. In rat plasma, only hydrox-
ylation metabolite M6 was detected, and in rat urine
M6 as well as secondary glucuronide metabolites of M6
(M2 and M9) were detected. This data suggests that
M6 is a relevant in vivo metabolism pathway, at least in
rat. In the absence of bile or feces metabolism data, fur-
ther interpretations such as the relevance of metabolic
clearance via dihydrodiol M3 cannot be made.
All human in vitro metabolites were also found in rat
hepatocytes, except for metabolite M1. This metabolite
is an N-glucuronide and is found in human, but not rat
hepatocytes, indicating the possible involvement of a hu-
man specific UDP-glucuronosyltransferase (UGT) [19] in
the metabolism of cryptolepine. According to the MIST
and ICH M3 (R2) health authority guidances [20], major
metabolites in human should be present in toxicology
species also, with the exception of most phase II metab-
olites. As such, glucuronide M1 would be excluded from
this assessment. With the similarities in the metabolites in
human and rat, the rat model therefore offers an appropri-
ate model for pre-clinical studies of cryptolepine.
In previous studies by Stell et al. (2012) [11], the in-
volvement of aldehyde oxidase in the metabolism of
cryptolepine was proposed, leading to the formation of
metabolite cryptolepine-11-one. The metabolites M6/M7
identified in this study in both human and rat hepatocytes
are formed by oxidative hydroxylation indicating that in-
volvement of aldehyde oxidase is possible. Metabolite
(M6) was also detected in rat plasma samples after oral
administration of cryptolepine. Aldehyde oxidase metabol-
ism has in the past caused difficulties in drug development,
as it is often more active in human than in preclinical
species. For example, a p38 kinase inhibitor (RO1) for
the treatment of rheumatoid arthritis was terminated
because of unexpected rapid clearance and short half-life
in man, proposed to be due to aldehyde oxidase metabol-
ism [12]. The aldehyde oxidase and N-glucuronidation
pathways could potentially result in significantly different
clearance and/or disposition in human compared to rat,
depending on the extent of formation and stability of each
metabolite in humans in vivo. The dihydroxylation metab-
olites (M3/M5) are likely to be formed via initial epoxide
formation, indicating the possibility of cytochrome P450
metabolism of cryptolepine. The proposed dihydrodiol
metabolites M3 and M5 were not found in rat in vivo, but
may be formed in the liver and excreted in feces.
Following intravenous and oral administration of cryp-
tolepine, rats exhibited high plasma clearance, extensive
distribution and low oral bioavailability. Elimination of
the unchanged drug in urine was negligible, suggesting
Table 2 Pharmacokinetic parameters of cryptolepine in rats following intravenous administration at a dose of 1 mg/kg
Animal ID Plasma AUC0–7h (nM.h) CLp (mL/min/kg) Vss (L/Kg) t1/2 (h) MRT (h) Urine Ae0-24h (% dose)
1 106 521 147 3 5 0.22
2 109 402 180 6 7 0.84
AUC0–7h, the area under the concentration-time curve up to the last measurable time point in plasma; CLp, plasma clearance; Vss, steady-state volume of distribution;
t1/2, elimination half-life; Tmax; MRT, mean residence time; Ae0-24h, amount excreted within 24 h following administration
Table 3 Pharmacokinetic parameters of cryptolepine in rats following oral administration at a dose of 5 mg/kg
Animal ID Plasma AUC0–7 (nM.h) Cmax (nM) Tmax (h) F % Urine Ae0-24h (% dose)
3 83 28 0.3 16 0.15
4 146 104 0.5 28 0.12
AUC0–7h, the area under the concentration-time curve up to the last measurable time point in plasma; Cmax, maximum plasma concentration; Tmax, time to reach
Cmax; F, oral bioavailability; Ae0-24h, amount excreted within 24 h following administration
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that renal elimination of unchanged drug is not a rele-
vant pathway of elimination. This is not surprising given
the physicochemical properties of cryptolepine, a rela-
tively lipophilic molecule (cLogP 4.3) which may lead to
a predisposition for elimination by metabolism [21, 22].
The in vivo study design used a single low dose of
cryptolepine to 2 animals per administration route. Due
to the relatively low concentrations in plasma, cryptole-
pine was only quantifiable up to 7 h post-dose. It is pos-
sible that due to this limitation, the full PK profile of
cryptolepine may not have been captured in vivo. How-
ever, the present investigation provides an additional as-
sessment of rat PK, in the same animals used for
metabolite identification. This in vivo study however was
a mere proof of concept hence the low sample size used.
More in depth radiolabelled cryptolepine and higher
dose studies allowing analysis of plasma and excreta over
a longer timeframe similar to mass balance excretion
studies as described in literature [23] may add further
in-depth knowledge of the absorption, distribution, me-
tabolism and excretion characteristics of cryptolepine in
rats.
Kuntworbe et al. (2013) [16] also showed an extensive
distribution of cryptolepine, with observed distribution
into the spleen, heart, lungs, kidney and liver coupled
with slow clearance from these tissues. Based on this
data and our new rat pharmacokinetic data, cryptolepine
is likely to extensively distribute in human, possibly accu-
mulating in vital organs and extending plasma residence
time. This property would be particularly advantageous
for the clearance of erythrocytic stage parasites, as accu-
mulation of antimalarial compounds into the food vacuole
of the plasmodium parasite has been associated with the
efficacy of these compounds [24].
Conclusions
In conclusion, this study revealed substantial information
about the metabolism of cryptolepine in rat and human,
as well as in vivo in SD rat. In rat and human hepatocytes,
nine metabolites were observed, with hydroxylation, dihy-
drodiol formation and glucuronidation proposed to be the
major metabolic pathways. Metabolites were qualitatively
similar between rat and human, and the metabolites found
in the rat urine and plasma also found in vitro, indicating
that rat is likely to be an appropriate preclinical species
for cryptolepine studies. Rat PK data indicated that cryp-
tolepine was cleared quickly from plasma, was extensively
distributed and was not extensively eliminated unchanged
in the urine. The data suggest that metabolism is likely a
pathway of elimination of cryptolepine but that renal elim-
ination is negligible.
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